Preferences for Attributes of Sodium Oxybate Treatment: A Discrete Choice Experiment in Patients with Narcolepsy

References

• Daniels E, King MA, Smith IE, Shneerson JM. Health-related quality of life in narcolepsy. J Sleep Res. 2001;10(1):75–81. doi:10.1046/j.1365-2869.2001.00234.x
   PubMed Web of Science ®Google Scholar
• Weaver TE, Mathias SD, Crosby RD, et al. Relationship between sleep efficacy endpoints and measures of functional status and health-related quality of life in participants with narcolepsy or obstructive sleep apnea treated for excessive daytime sleepiness. J Sleep Res. 2021;30(3):e13210. doi:10.1111/jsr.13210
   PubMed Web of Science ®Google Scholar
• Tadrous R, O’Rourke D, Mockler D, Broderick J. Health-related quality of life in narcolepsy: a systematic review and meta-analysis. J Sleep Res. 2021;30(6):e13383. doi:10.1111/jsr.13383
   Web of Science ®Google Scholar
• Ingravallo F, Gnucci V, Pizza F, et al. The burden of narcolepsy with cataplexy: how disease history and clinical features influence socio-economic outcomes. Sleep Med. 2012;13(10):1293–1300. doi:10.1016/j.sleep.2012.08.002
   PubMed Web of Science ®Google Scholar
• Thorpy MJ. Recently approved and upcoming treatments for narcolepsy. CNS Drugs. 2020;34(1):9–27. doi:10.1007/s40263-019-00689-1
   PubMed Web of Science ®Google Scholar
• Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654–2662. doi:10.1056/NEJMra1500587
   PubMed Web of Science ®Google Scholar
• Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881–1893. doi:10.5664/jcsm.9328
   PubMed Web of Science ®Google Scholar
• Roth T, Dauvilliers Y, Guinta D, Alvarez-Horine S, Dynin E, Black J. Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy. J Sleep Res. 2017;26(4):407–414. doi:10.1111/jsr.12468
   PubMed Web of Science ®Google Scholar
• XYREM (sodium oxybate oral solution, CIII) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals; 2020.
   Google Scholar
• XYWAV (calcium, magnesium, potassium, and sodium oxybates) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals; 2021.
   Google Scholar
• Center for Drug Evaluation and Research (CDER). The Voice of the Patient: Narcolepsy. US Food and Drug Administration; 2014.
   Google Scholar
• Pérez-Carbonell L, Lyons E, Gnoni V, et al. Adherence to wakefulness promoting medication in patients with narcolepsy. Sleep Med. 2020;70:50–54. doi:10.1016/j.sleep.2020.02.013
   PubMed Web of Science ®Google Scholar
• Rogers AE, Aldrich MS, Berrios AM, Rosenberg RS. Compliance with stimulant medications in patients with narcolepsy. Sleep. 1997;20(1):28–33. doi:10.1093/sleep/20.1.28
   PubMed Web of Science ®Google Scholar
• Mayer G, Plazzi G, Iranzo A, et al. Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1: a postauthorization, noninterventional surveillance study. Sleep. 2018;41(9):zsy128. doi:10.1093/sleep/zsy128
   Web of Science ®Google Scholar
• Weeda ER, Coleman CI, McHorney CA, Crivera C, Schein JR, Sobieraj DM. Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: a meta-regression analysis. Int J Cardiol. 2016;216:104–109. doi:10.1016/j.ijcard.2016.04.082
   PubMed Web of Science ®Google Scholar
• Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527–539. doi:10.18553/jmcp.2012.18.7.527
   PubMed Web of Science ®Google Scholar
• Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012;28(5):669–680. doi:10.1185/03007995.2012.677419
   PubMed Web of Science ®Google Scholar
• Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15(6):e22–e33.
   PubMed Web of Science ®Google Scholar
• Laliberte F, Bookhart BK, Nelson WW, et al. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient. 2013;6(3):213–224. doi:10.1007/s40271-013-0020-5
   PubMedGoogle Scholar
• Kushida CA, Shapiro CM, Roth T, et al. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy. Sleep.2021;zsab200. doi: 10.1093/sleep/zsab200
   Web of Science ®Google Scholar
• U. S. Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002;25(1):42–49. doi:10.1093/sleep/25.1.42
   PubMed Web of Science ®Google Scholar
• U. S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004;5(2):119–123. doi:10.1016/j.sleep.2003.11.002
   PubMed Web of Science ®Google Scholar
• Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2005;1(4):391–397. doi:10.5664/jcsm.26368
   PubMed Web of Science ®Google Scholar
• Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29(7):939–946. doi:10.1093/sleep/29.7.939
   PubMed Web of Science ®Google Scholar
• Yang JC, Johnson FR, Kilambi V, Mohamed AF. Sample size and utility-difference precision in discrete-choice experiments: a meta-simulation approach. J Choice Model. 2015;16:50–57. doi:10.1016/j.jocm.2015.09.001
   Web of Science ®Google Scholar
• Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CG, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health. 2016;19(4):300–315. doi:10.1016/j.jval.2016.04.004
   PubMed Web of Science ®Google Scholar
• Eatock J, Baker GA. Managing patient adherence and quality of life in epilepsy. Neuropsychiatr Dis Treat. 2007;3(1):117–131. doi:10.2147/nedt.2007.3.1.117
   PubMedGoogle Scholar
• Sunny AA, Iyer RS, Kumaran SG, Bunshaw NG, Shanmugham K, Govindaraj U. Affordability, availability and tolerability of anti-seizure medications are better predictors of adherence than beliefs: changing paradigms from a low resource setting. Seizure. 2020;83:208–215. doi:10.1016/j.seizure.2020.11.003
   PubMed Web of Science ®Google Scholar